Showing results (751-760 of 1,068) with videos related to
Sort By:
Pageof 107
Journal of Pharmacokinetics and Pharmacodynamics|March 21, 2015
Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatmentMatts Kågedal, Mats O Karlsson, Andrew C HookerJournal of Pharmacokinetics and Pharmacodynamics|August 4, 2022
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervalsChuanpu HuJournal of Pharmacokinetics and Pharmacodynamics|May 12, 2021
Concentration-QTc analysis with two or more correlated baselinesYasushi Orihashi, Yuji KumagaiJournal of Pharmacokinetics and Pharmacodynamics|February 15, 2023
A next generation mathematical model for the in vitro to clinical translation of T-cell engagersDavid Flowers, David Bassen, Georgi I Kapitanov, et al.Journal of Pharmacokinetics and Pharmacodynamics|November 14, 2022
Pharmacometric model of agalsidase-migalastat interaction in human: a novel mechanistic model of drug-drug interaction between a therapeutic protein and a small moleculeThanh Bach, Nan Wu, Guohua AnJournal of Pharmacokinetics and Pharmacodynamics|January 6, 2026
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I dataMaddlie Bardol, Andrea Henrich, Celine Sarr, et al.Journal of Pharmacokinetics and Pharmacodynamics|October 28, 2025
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD modelKeyur R Parmar, Agnish Dey, Angelia F Wang, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2025
Advancing drug development with "Fit-for-Purpose" modeling informed approachesJennifer Sheng, Tongli ZhangJournal of Pharmacokinetics and Pharmacodynamics|September 27, 2025
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approaches - further results based on more conventional practicesMorgane Philipp, Simon Buatois, Sylvie Retout, et al.Journal of Pharmacokinetics and Pharmacodynamics|July 28, 2025
Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncologyShruti D Shah, Roxanne C Jewell, Geraldine Ferron-Brady, et al.Pageof 107